Doctors' policy on explaining the implementation of novel experimental treatment to cancer patients.
This article deals with the extent of information which should be provided by doctors to cancer patients prior to the implementation of experimental treatment. It describes the various factors which affect the extent of information disclosed. The study compared oncological patients to vascular patients. From the results of the research one can see that doctors in Israel provide extensive information about the nature of the medicine as well as side-effects and expected benefits prior to the experimental treatment, yet they give less information concerning the hazards involved in the treatment. Information offered by doctors treating oncological patients is more extensive than that offered by internal doctors treating vascular patients.
Tabak
N
N
Department of Nursing, Tel Aviv University, Ramat Aviv, Israel.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D006805:Human Experimentation; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence*; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D010353:Patient Education as Topic / Q000331:legislation & jurisprudence*; D010819:Physician's Role; D010817:Physician-Patient Relations
D015251:Epirubicin; D003606:Dacarbazine; D007372:Interferons